Summarizing performance for genome scale measurement of miRNA: reference samples and metrics

BMC Genomics

卷:19

Ashish A. Mahabal¹  Barry A. Rosenzweig²  Karol L. Thompson²  Chandra Goparaju³  Harvey I. Pass³  Steven M. Dubinett⁴  Kostyantyn Krysan⁴  Debra Kukuruga⁵  Sanford A. Stass⁵  Lynn Sorbara⁶  Sudhir Srivastava⁶  Heather Kincaid⁷  Luca Cinquini⁷  Sean C. Kelly⁷  Daniel J. Crichton⁷  Lindsay K. Vang⁸  Jerod R. Parsons⁸  Marc L. Salit⁸  P. Scott Pine⁸  Gang Liu⁹  Adam C. Gower⁹  Avrum Spira⁹  Steven P. Lund¹⁰  Amanda Courtright-Lim¹¹  Kendall Van Keuren-Jensen¹¹ 

[1] Center for Data Driven Discovery, California Institute of Technology;

[2] Center for Drug Evaluation and Research, Food and Drug Administration;

[3] Department of Cardiothoracic Surgery, NYU Langone Medical Center;

[4] Department of Medicine, David Geffen School of Medicine at UCLA;

[5] Department of Pathology, University of Maryland School of Medicine;

[6] Division of Cancer Prevention, National Cancer Institute;

[7] Jet Propulsion Laboratory, California Institute of Technology;

[8] Joint Initiative for Metrology in Biology, National Institute of Standards and Technology;

[9] Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine;

[10] Statistical Engineering Division, National Institute of Standards and Technology;

[11] Translational Genomics Research Institute;

关键词: microRNA;    miRNA;    Reference samples;    Process controls;    Dashboard;   

DOI  :  10.1186/s12864-018-4496-1

来源: DOAJ

【 摘 要 】

Abstract Background The potential utility of microRNA as biomarkers for early detection of cancer and other diseases is being investigated with genome-scale profiling of differentially expressed microRNA. Processes for measurement assurance are critical components of genome-scale measurements. Here, we evaluated the utility of a set of total RNA samples, designed with between-sample differences in the relative abundance of miRNAs, as process controls. Results Three pure total human RNA samples (brain, liver, and placenta) and two different mixtures of these components were evaluated as measurement assurance control samples on multiple measurement systems at multiple sites and over multiple rounds. In silico modeling of mixtures provided benchmark values for comparison with physical mixtures. Biomarker development laboratories using next-generation sequencing (NGS) or genome-scale hybridization assays participated in the study and returned data from the samples using their routine workflows. Multiplexed and single assay reverse-transcription PCR (RT-PCR) was used to confirm in silico predicted sample differences. Data visualizations and summary metrics for genome-scale miRNA profiling assessment were developed using this dataset, and a range of performance was observed. These metrics have been incorporated into an online data analysis pipeline and provide a convenient dashboard view of results from experiments following the described design. The website also serves as a repository for the accumulation of performance values providing new participants in the project an opportunity to learn what may be achievable with similar measurement processes. Conclusions The set of reference samples used in this study provides benchmark values suitable for assessing genome-scale miRNA profiling processes. Incorporation of these metrics into an online resource allows laboratories to periodically evaluate their performance and assess any changes introduced into their measurement process.

【 授权许可】

Unknown